Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07105709 · ClinicalTrials.gov registry record · Phase 2
Open-label Extension Study in Participants With Early Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT07105709 is a Phase 2 study of Alzheimers Disease that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 220 participants, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT07105709, a Phase 2 study of Alzheimers Disease, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment \[MCI\] and mild dementia due to AD) who have completed the parent study.
Conditions Studied
Interventions
- DRUG GSK4527226
Study Locations (20)
Other
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Ciudad Autonoma de Buenos Aire
- GSK Investigational Site - Ciudad Autonoma de Bueno
Florida
- GSK Investigational Site - Maitland
- GSK Investigational Site - Miami
- GSK Investigational Site - Stuart
Ontario
- GSK Investigational Site - Ottawa
- GSK Investigational Site - Peterborough
- GSK Investigational Site - Toronto
Quebec
- GSK Investigational Site - Greenfield Park
- GSK Investigational Site - Sherbrooke
New Jersey
- GSK Investigational Site - Toms River
New York
- GSK Investigational Site - Staten Island
North Carolina
- GSK Investigational Site - Matthews
Oklahoma
- GSK Investigational Site - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-08-14 |
| Est. Completion | 2028-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07105709
The ClinicalTrials.gov registry entry for NCT07105709 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (95% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which GSK4527226 is the first listed.
NCT07105709 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Ontario.
Frequently Asked Questions
What is clinical trial NCT07105709 about?
NCT07105709 is a clinical study titled "Open-label Extension Study in Participants With Early Alzheimer's Disease". The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same s...
What is the current status of trial NCT07105709?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2025-08-14. Estimated completion is 2028-12-08.
What conditions does trial NCT07105709 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT07105709?
The interventions under investigation include: GSK4527226 (DRUG).
Who is sponsoring clinical trial NCT07105709?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07105709 being conducted?
This trial has 20 study locations across Florida, New Jersey, New York, North Carolina, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.